argenx NV ADR (ARGX) - Total Assets
Based on the latest financial reports, argenx NV ADR (ARGX) holds total assets worth $10.03 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
argenx NV ADR - Total Assets Trend (2010–2025)
This chart illustrates how argenx NV ADR's total assets have evolved over time, based on quarterly financial data. Also see market cap of argenx NV ADR for the company's overall valuation and market capitalisation.
argenx NV ADR - Asset Composition Analysis
Current Asset Composition (December 2025)
argenx NV ADR's total assets of $10.03 Billion consist of 79.5% current assets and 20.5% non-current assets. Review total liabilities of argenx NV ADR to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.2% |
| Accounts Receivable | $1.66 Billion | 19.1% |
| Inventory | $473.53 Million | 5.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $272.10 Million | 3.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how argenx NV ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest argenx NV ADR stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: argenx NV ADR's current assets represent 79.5% of total assets in 2025, a decrease from 97.0% in 2010.
- Cash Position: Cash and equivalents constituted 40.2% of total assets in 2025, down from 85.7% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 19.1% of total assets.
argenx NV ADR Competitors by Total Assets
Key competitors of argenx NV ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
PYC Therapeutics Ltd
AU:PYC
|
Australia | AU$183.28 Million |
argenx NV ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.12 | 5.60 | 11.74 |
| Quick Ratio | 4.89 | 5.27 | 11.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.49 Billion | $4.79 Billion | $2.62 Billion |
argenx NV ADR - Advanced Valuation Insights
This section examines the relationship between argenx NV ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.68 |
| Latest Market Cap to Assets Ratio | 5.29 |
| Asset Growth Rate (YoY) | 40.0% |
| Total Assets | $8.68 Billion |
| Market Capitalization | $45.97 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values argenx NV ADR's assets at a significant premium (5.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: argenx NV ADR's assets grew by 40.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for argenx NV ADR (2010–2025)
The table below shows the annual total assets of argenx NV ADR from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $8.68 Billion | +39.99% |
| 2024-12-31 | $6.20 Billion | +36.55% |
| 2023-12-31 | $4.54 Billion | +44.93% |
| 2022-12-31 | $3.13 Billion | +9.96% |
| 2021-12-31 | $2.85 Billion | +25.04% |
| 2020-12-31 | $2.28 Billion | +41.56% |
| 2019-12-31 | $1.61 Billion | +143.35% |
| 2018-12-31 | $661.70 Million | +48.70% |
| 2017-12-31 | $444.98 Million | +300.01% |
| 2016-12-31 | $111.24 Million | +121.38% |
| 2015-12-31 | $50.25 Million | -14.12% |
| 2014-12-31 | $58.51 Million | +69.40% |
| 2013-12-31 | $34.54 Million | +50.63% |
| 2012-12-31 | $22.93 Million | -28.21% |
| 2011-12-31 | $31.94 Million | +160.51% |
| 2010-12-31 | $12.26 Million | -- |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more